SCHEMBL26260734

SCHEMBL26260734

Fc1cccc(Nc2ccc3[nH]c(COc4ccnc(C(F)(F)F)c4)nc3c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.40
▸ RAB9A P51151 8/20 0.40
▸ SMN1; SMN2 Q16637 7/20 0.40
▸ TP53 P04637 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ PDE10A Q9Y233 2/20 0.39
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040122 0.91 RAB9A (0.44) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL25400113 0.91 RAB9A (0.44) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL26262078 0.86 NPC1 (0.43) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL30041546 0.86 RAB9A (0.41) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL26260731 0.86 RAB9A (0.41) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL23618342 0.83 IDH2 (0.41) PDE10AHDAC1HDAC8HDAC6GRM4
SCHEMBL30040258 0.83 IDH2 (0.41) PDE10AHDAC1HDAC8HDAC6GRM4
SCHEMBL26260736 0.83 SMN1; SMN2 (0.45) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL30041208 0.83 SMN1; SMN2 (0.45) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL30041878 0.82 ABCB1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085054-B1 NEW PQSR INVERSE AGONISTS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-02-19 — — EP disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed
EP-4085054-A1 NEW PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286942-A1 NEW PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 NPC1 4374/4885RAB9A 991/4885SMN1; SMN2 4177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback